COVID-19 vaccine (Astrazeneca) and thromboembolic events with concurrent low platelet counts

 I am writing to you following the CMO letter HSS(MD) 28/2021 (dated 8th April 2021) to outline the operational procedures which should be followed for any patient reporting symptoms suggestive of a blood clot more than 4 days and within 28 days from receiving a dose of Astrazeneca vaccine. The following symptoms suggest the need for urgent medical investigation: 

 new onset of severe headache, which is getting worse and does not respond to simple painkillers 

 an unusual headache which seems worse when lying down or bending over, or may be accompanied by blurred vision, nausea and vomiting, difficulty with speech, weakness, drowsiness or seizures 

 new unexplained pinprick bruising or bleeding 

 shortness of breath, chest pain, leg swelling 

 persistent abdominal pain 

200421 - ltr re AZ vaccine and VITTs